SCHEMBL5162674

SCHEMBL5162674

CC(=O)Nc1cc2c3c(cccc3c1)C(=O)N(c1ccc(S(=O)(=O)O)cc1)C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 1/20 0.54
SCN2A Q99250 1/20 0.52
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
BLM P54132 1/20 0.51
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
KDM4E B2RXH2 3/20 0.49
MAPT P10636 1/20 0.49
ALDH1A1 P00352 5/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
GAA P10253 1/20 0.47
CASP6 P55212 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150616 0.92 ALDH1A1 (0.53) KLK7SCN2AKMT2AMEN1USP2
SCHEMBL5533044 0.84 MAPK1 (0.52) KLK7SCN2AKMT2AMEN1USP2
SCHEMBL5154497 0.79 CA12 (0.60) SCN2AKMT2AMEN1CA12CA9
SCHEMBL5148383 0.79 KLK7 (0.55) KLK7SCN2AKMT2AMEN1USP2
SCHEMBL5533314 0.76 CA12 (0.79) SCN2AKMT2AMEN1CA12CA9
SCHEMBL5160041 0.75 KLK7 (0.55) KLK7SCN2AKMT2AMEN1USP2
SCHEMBL7709436 0.75 KLK7 (0.61) KLK7SCN2AKMT2AMEN1USP2
SCHEMBL5123962 0.74 KDM4E (0.64) KLK7KMT2AMEN1CA12CA9
SCHEMBL5159288 0.73 MEN1 (0.60) KLK7SCN2AKMT2AMEN1CA12
SCHEMBL20508117 0.72 MEN1 (0.59) SCN2AKMT2AMEN1CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US claimed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO claimed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2007-05-31 US disclosed
WO-2007030939-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123514-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 KLK7 2172/4885SCN2A 1537/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.